Hims stock surges after deal with Novo Nordisk
Prior to March 9, 2026, Hims & Hers Health faced significant challenges in the market, particularly following the collapse of a previous agreement with Novo Nordisk in June. The company had been selling lower-cost compounded versions of semaglutide, which led to a lawsuit from Novo Nordisk over patent infringement. Investors were concerned about the potential legal ramifications and the impact on Hims’ market position.
However, a decisive moment occurred when reports emerged of a new deal between Hims & Hers and Novo Nordisk. This agreement allows Hims & Hers to sell Novo Nordisk’s weight-loss medicine on its platform, a significant shift that has positively influenced investor sentiment. Following the announcement, Hims & Hers stock surged by 53.1 percent in premarket trading, reaching a price of $24.1.
The immediate effects of this development were felt not only by Hims & Hers but also by Novo Nordisk. While Hims & Hers experienced a substantial increase in stock value, Novo Nordisk’s shares rose by 0.8 percent, indicating a positive reception from the market regarding the partnership.
This new agreement effectively ends the ongoing lawsuit aimed at stopping Hims from selling its copycat version of Wegovy, which had been a point of contention between the two companies. The resolution of this legal dispute is expected to provide Hims & Hers with a clearer path forward in the competitive weight-loss market.
Experts suggest that the partnership could enhance Hims & Hers’ product offerings and market reach, potentially attracting a broader customer base seeking weight-loss solutions. The collaboration with Novo Nordisk, a leader in the pharmaceutical industry, may also lend credibility to Hims & Hers’ platform.
While the deal marks a significant turnaround for Hims & Hers, it is essential to consider the broader implications for the healthcare market. The partnership could set a precedent for similar collaborations between telehealth companies and established pharmaceutical firms, potentially reshaping how medications are marketed and sold.
Details remain unconfirmed regarding the specific terms of the agreement and how it will be implemented in the coming months. However, the initial market reaction indicates a strong belief in the potential success of this partnership.
As Hims & Hers continues to navigate the complexities of the healthcare landscape, this deal with Novo Nordisk may represent a pivotal moment in its growth trajectory, providing new opportunities for expansion and innovation in the health and wellness sector.